AnnickDesjardinsMDFRCPC

Neurology • Durham, NC

Neurooncology

Associate Professor of Neurology, Duke University School of Medicine

Join to view full profile

Dr. Desjardins is on Doximity

As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.

Connect with other colleagues in the same hospital or clinic
Search all U.S. specialist profiles and refer a patient
Read the latest clinical news and earn CME/CEU credits

See Dr. Desjardins' full profile

Already have an account?

Office
20 Duke Medicine Cir
Durham, NC 27710
Phone+1 919-684-5301

Fax+1 919-684-6674
Is this information wrong?

Education & Training

University Sherbrooke Faculty Medicine HospitalNeurology, 1998 - 2003
University of Sherbrooke Faculty of MedicineClass of 1998

Certifications & Licensure

NC State Medical License 2003 - 2025

Awards, Honors, & Recognition

CMS Meaningful Use Stage 1 Certification EpicCare Ambulatory EMR, Epic Systems Corporation, 2013

Clinical Trials

Phase 2 Study of Panzem Nanocrystal Colloidal Dispersion (NCD) in Combination With Fixed-Dose Temozolomide to Patients With Recurrent Glioblastoma Multiforme (GBM) Start of enrollment: 2007 Apr 01
Completed
Phase 2
Bevacizumab in Combination With Metronomic Temozolomide for Recurrent Malignant Glioma Start of enrollment: 2007 Jul 01
Completed
Phase 2
Avastin in Combination With Radiation (XRT) & Temozolomide, Followed by Avastin, Temozolomide and Irinotecan for Glioblastoma (GBM) and Gliosarcomas Start of enrollment: 2007 Jul 01
Completed
Phase 2
Ph I Dasatinib + Erlotinib in Recurrent MG Start of enrollment: 2008 Jan 01
Completed
Phase 1
PH I Addition of Farnesyl Transferase Inhibitor to Temozolomide for Pts w Gr 3 & 4 Malignant Gliomas Start of enrollment: 2005 Oct 01
Completed
Phase 1
Ph I Zactima + Imatinib Mesylate & Hydroxyurea for Pts w Recurrent Malignant Glioma Start of enrollment: 2007 Nov 01
Completed
Phase 1
Ph I Gleevec in Combo w RAD001 + Hydroxyurea for Pts w Recurrent MG Start of enrollment: 2005 May 01
Completed
Phase 1
Ph I Dose Escalation Trial of Vandetanib in Combo w Etoposide for Malignant Gliomas Start of enrollment: 2008 Feb 01
Completed
Phase 1
Phase II Imatinib + Hydroxyurea in Treatment of Patients With Recurrent/Progressive Grade II Low-Grade Glioma (LGG) Start of enrollment: 2006 Feb 01
Completed
Phase 2
Ph. I Dasatinib/Protracted Temozolomide in Recurrent Malignant Glioma Start of enrollment: 2009 Jun 01
Withdrawn
Phase 1
A Study of Gliadel Followed by Avastin + Irinotecan for Glioblastoma Multiforme (GBM) Start of enrollment: 2008 Dec 01
Terminated
Phase 2
Bevacizumab Plus Irinotecan Plus Carboplatin for Recurrent Malignant Glioma (MG) Start of enrollment: 2009 Sep 01
Completed
Phase 2
Pharmacokinetics (PK) Study of AC480 for Recurrent Glioma Start of enrollment: 2009 Nov 01
Completed
Phase 1
Avastin/Radiation (XRT)/Temozolomide (Temodar) Followed by Avastin/Temodar/Topotecan for Glioblastoma Start of enrollment: 2009 Dec 30
Completed
Phase 2
Study of Immunotoxin, MR1-1 Start of enrollment: 2006 Nov 01
Terminated
Phase 1
Panitumumab and Irinotecan for Malignant Gliomas Start of enrollment: 2010 Feb 01
Terminated
Phase 2
Gliadel, XRT, Temodar, Avastin Followed by Avastin, Temodar for Newly Diagnosed Glioblastoma Multiforme (GBM) Start of enrollment: 2011 Apr 01
Terminated
Phase 2
A Study of Rindopepimut/GM-CSF in Patients With Relapsed EGFRvIII-Positive Glioblastoma Start of enrollment: 2011 Dec 01
Completed
Phase 2
Pilot Study of Bone Marrow/Stem Cells in Grade IV Malignant Glioma Start of enrollment: 2012 Jun 01
Completed
Phase 1
Bevacizumab Beyond Progression (BBP) Start of enrollment: 2013 Jan 01
Completed
Phase 2
Phase 1/2 CTO + Bevacizumab for Recurrent Glioma Post-Bevacizumab Failure Start of enrollment: 2013 Oct 01
Terminated
Phase 1
Ph 1/2 CTO With Lomustine for Bevacizumab-Naive Recurrent Glioma Start of enrollment: 2014 May 01
Terminated
Phase 1
Phase 2 Study of Sym004 for Adult Patients With Recurrent Glioblastoma Start of enrollment: 2016 Feb 01
Completed
Phase 2
Intracerebral EGFR-vIII CAR-T Cells for Recurrent GBM Start of enrollment: 2018 May 30
Terminated
Phase 1
Seizure Prophylaxis in Patients With Glioma or Brain Metastasis Start of enrollment: 2019 Jan 31
Terminated
Phase 2
DC Migration Study to Evaluate TReg Depletion In GBM Patients With and Without Varlilumab Start of enrollment: 2020 Aug 26
Active, not recruiting
Phase 2
Monocyte Antigen Carrier Cells for Newly Diagnosed GBM Start of enrollment: 2023 Aug 01
Withdrawn
Phase 1
Join now to see all

Publications & Presentations

PubMed

Use, access, and initial outcomes of off-label ivosidenib in patients with IDH1 mutant glioma.
Katherine B Peters, Candice Alford, Amy Heltemes, Alicia Savelli, Daniel B Landi, Gloria Broadwater, Margaret O Johnson, Justin T Low, David M Ashley, Mallika P Patel,...> ;Neuro-Oncology Practice. 2024 Apr 1
7 citations
Correcting the drug development paradigm for glioblastoma requires serial tissue sampling.
Kirit Singh, Kelly M Hotchkiss, Ian F Parney, John De Groot, Solmaz Sahebjam, Nader Sanai, Michael Platten, Evanthia Galanis, Michael Lim, Patrick Y Wen, Giuseppe Minn...> ;Nature Medicine. 2023 Oct 1
1 citations
Intratumor childhood vaccine-specific CD4T-cell recall coordinates antitumor CD8T cells and eosinophils.
Michael C Brown, Georgia M Beasley, Zachary P McKay, Annick Desjardins, Dina M Randazzo, Daniel Landi, David M Ashley, Darell D Bigner, Smita K Nair, Matthias Gromeier...> ;Journal for Immunotherapy of Cancer. 2023 Apr 1
6 citations
Recombinant polio-rhinovirus immunotherapy for recurrent paediatric high-grade glioma: a phase 1b trial.
Eric M Thompson, Daniel Landi, Michael C Brown, Henry S Friedman, Roger McLendon, James E Herndon 2nd, Evan Buckley, Dani P Bolognesi, Eric Lipp, Kristin Schroeder, Or...> ;The Lancet. Child & Adolescent Health. 2023 Jul 1
4 citations
Immunotoxin-αCD40 therapy activates innate and adaptive immunity and generates a durable antitumor response in glioblastoma models.
Scott Parker, Charlotte McDowall, Luis Sanchez-Perez, Cristina Osorio, Patrick C Duncker, Aaron Briley, Adam M Swartz, James E Herndon 2nd, Yen-Rei A Yu, Roger E McLen...> ;Science Translational Medicine. 2023 Feb 8
Improving survival in neuro-oncology is a struggle; we cannot allow ourselves to also struggle with issues of diversity.
Annick Desjardins> ;Neuro-Oncology. 2022 Aug 1
10 citations
Oncolytic Viral Therapy for Malignant Glioma and Their Application in Clinical Practice.
Madison L Shoaf, Annick Desjardins> ;Neurotherapeutics. 2022 Oct 1
3 citations
Effects of low-dose naltrexone on quality of life in high-grade glioma patients: a placebo-controlled, double-blind randomized trial.
Katherine B Peters, Mary L Affronti, Sarah Woodring, Eric Lipp, Patrick Healy, James E Herndon 2nd, Elizabeth S Miller, Maria W Freeman, Dina M Randazzo, Annick Desjar...> ;Supportive Care in Cancer. 2022 Apr 1
8 citations
Convection-enhanced delivery for high-grade glioma.
Jennifer H Kang, Annick Desjardins> ;Neuro-Oncology Practice. 2022 Feb 1
6 citations
Long-Term Outcomes for Patients With Atypical or Malignant Meningiomas Treated With or Without Radiation Therapy: A 25-Year Retrospective Analysis of a Single-Institut...
Collin L Kent, Yvonne M Mowery, Olayode Babatunde, Ato O Wright, Ian Barak, Frances McSherry, James E Herndon 2nd, Allan H Friedman, Ali Zomorodi, Katherine Peters, An...> ;Advances in Radiation Oncology. 2021 Dec 24
2 citations
Primary brain tumor patients admitted to a US intensive care unit: a descriptive analysis.
Jennifer H. Kang, Christa B. Swisher, Evan Buckley, James E. Herndon, Eric S. Lipp, John P. Kirkpatrick, Annick Desjardins, Henry S. Friedman, Margaret Johnson, Dina R...> ;CNS Oncology. 2021 Sep 1
1 citations
Repeatability of Automated Image Segmentation with BraTumIA in Patients with Recurrent Glioblastoma.
N. Abu Khalaf, Annick Desjardins, James J. Vredenburgh, Daniel P. Barboriak> ;AJNR. American Journal of Neuroradiology. 2021 Mar 18
4 citations
Spiritual well-being and its association with health-related quality of life in primary brain tumor patients.
Dina Randazzo, Frances McSherry, James E. Herndon, Mary Lou Affronti, Eric S. Lipp, Elizabeth S Miller, Sarah Woodring, Patrick Healy, Jennifer G. Jackman, Brian T. Cr...> ;Neuro-Oncology Practice. 2021 May 26
71 citations
Very low mutation burden is a feature of inflamed recurrent glioblastomas responsive to cancer immunotherapy.
Matthias Gromeier, Michael C. Brown, Gao Zhang, Xiang Lin, Yeqing Chen, Zhi Wei, Nike Beaubier, Hai Yan, Yiping He, Annick Desjardins, James E. Herndon, Frederick S. V...> ;Nature Communications. 2021 Jan 13
18 citations
Marizomib alone or in combination with bevacizumab in patients with recurrent glioblastoma: Phase I/II clinical trial data.
Daniela A. Bota, Warren P. Mason, Santosh Kesari, Rajiv Magge, Benjamin Winograd, Ileana Elias, Steven D. Reich, Nancy Levin, Mohit Trikha, Annick Desjardins> ;Neuro-Oncology Advances. 2021 Jan 1
Adjuvant Radiation in Older Patients With Glioblastoma: A Retrospective Single Institution Analysis.
Jessica W. Lee, John P. Kirkpatrick, Frances McSherry, James E. Herndon, Eric S. Lipp, Annick Desjardins, Dina Randazzo, Henry S. Friedman, David M. Ashley, Katherine ...> ;Frontiers in Oncology. 2021 Feb 25
28 citations
A phase 1 study of PF-06840003, an oral indoleamine 2,3-dioxygenase 1 (IDO1) inhibitor in patients with recurrent malignant glioma.
David A. Reardon, Annick Desjardins, Olivier Rixe, Timothy F. Cloughesy, Shilpa Alekar, Jason H. Williams, Ray Li, Carrie T. Taylor, Andrew B. Lassman> ;Investigational New Drugs. 2020 May 20
9 citations
Randomized open-label phase II trial of 5-day aprepitant plus ondansetron compared to ondansetron alone in the prevention of chemotherapy-induced nausea-vomiting (CINV...
Mallika P Patel, Sarah Woodring, Dina Randazzo, Henry S. Friedman, Annick Desjardins, Patrick Healy, James E. Herndon, Frances McSherry, Eric S. Lipp, Elizabeth Miller...> ;Supportive Care in Cancer. 2020 May 1
4 citations
Patterns of relapse after successful completion of initial therapy in primary central nervous system lymphoma: a case series.
Mallika P Patel, John P. Kirkpatrick, Margaret Johnson, Patrick Healy, James E. Herndon, Eric S. Lipp, Elizabeth S Miller, Annick Desjardins, Dina Randazzo, Henry S. F...> ;Journal of Neuro-Oncology. 2020 Mar 5
61 citations
Phase 1b/2a study of galunisertib, a small molecule inhibitor of transforming growth factor-beta receptor I, in combination with standard temozolomide-based radiochemo...
Antje Wick, Annick Desjardins, Cristina Suarez, Peter A. Forsyth, Ivelina Gueorguieva, Tiana L. Burkholder, Ann Cleverly, Shawn T. Estrem, Shuaicheng Wang, Michael Lah...> ;Investigational New Drugs. 2020 Mar 5
86 citations
Rindopepimut with Bevacizumab for Patients with Relapsed EGFRvIII-Expressing Glioblastoma (ReACT): Results of a Double-Blind Randomized Phase II Trial.
, , , , , , , , , , , , , , , , , , , , > ;Clinical Cancer Research. 2020 Feb 7
5 citations
The role of chemotherapy in the treatment of central neurocytoma.
Margaret Johnson, John P. Kirkpatrick, Mallika P Patel, Annick Desjardins, Dina Randazzo, Henry S. Friedman, David M. Ashley, Katherine B. Peters> ;CNS Oncology. 2019 Nov 1
11 citations
Second primary cancers in long-term survivors of glioblastoma
Jung-Young Kim, Jennifer G. Jackman, Sarah Woodring, Frances McSherry, James E. Herndon, Annick Desjardins, Henry S. Friedman, Katherine B. Peters> ;Neuro-Oncology Practice. 2019 Sep 20
5 citations
Complementary and integrative health interventions and their association with health-related quality of life in the primary brain tumor population
Dina Randazzo, Frances McSherry, James E. Herndon, Mary Lou Affronti, Eric S. Lipp, Charlene Flahiff, Elizabeth Miller, Sarah Woodring, Susan Boulton, Annick Desjardin...> ;Complementary Therapies in Clinical Practice. 2019 Aug 1
31 citations
Improved efficacy against malignant brain tumors with EGFRwt/EGFRvIII targeting immunotoxin and checkpoint inhibitor combinations
Vidyalakshmi Chandramohan, Xuhui Bao, Xin Yu, Scott Parker, Charlotte McDowall, Yen-Rei A. Yu, Patrick Healy, Annick Desjardins, Michael D. Gunn, Matthias Gromeier, Sm...> ;Journal for Immunotherapy of Cancer. 2019 May 29
Join now to see all

Lectures

Oncolytic polio/rhinovirus recombinant (PVSRIPO) against WHO grade IV malignant glioma (MG): Experience with retreatment of survivors from the phase I trial.
2019 ASCO Annual Meeting - 6/1/2019

Press Mentions

The EndBrainCancer Initiative to Feature Renowned Brain Cancer and Modified Poliovirus Duke Researcher, Dr. Annick Desjardins, as Its Keynote Speaker for the 2019 Annual May "Brains Matter" ACTION Dinner as Advocacy Is Underway Now to Bring This Treatm...May 9th, 2019
Early Results for Oncolytic Viruses as a Treatment for Glioblastoma in Both Adults and ChildrenAugust 24th, 2018
Doctors Are Using Herpes Virus to Fight Brain Cancer, and It’s WorkingAugust 17th, 2018
Join now to see all